Dayvigo Sexual Function Impact: What the Evidence Actually Shows

What Dayvigo Is Actually Approved To Do

Dayvigo is approved to treat adult insomnia characterized by difficulty with sleep onset or sleep maintenance. DailyMed lists 5 mg taken before bed, with at least seven hours remaining before planned awakening, as the recommended starting dose; 10 mg is the maximum recommended dose. The label's major safety themes include next-day impairment, central nervous system depression, sleep paralysis, hypnagogic or hypnopompic hallucinations, complex sleep behaviors, worsening depression or suicidal ideation, and contraindication in narcolepsy. [1]

Sexual dysfunction is not a named adverse reaction in the current label. That should be communicated accurately: the absence of a named label reaction is different from proof that the drug is sexually neutral for everyone. In SUNRISE-1, lemborexant was studied for sleep onset and maintenance in older adults; the trial was not designed around validated sexual-function outcomes. [2]

Why the Evidence Is Easy To Overstate

Orexin signaling is central to maintaining wakefulness, but broad neurobiology reviews do not predict a patient's sexual response to lemborexant. [5] A small study in healthy men found an association between sleep architecture and nocturnal testosterone secretion. [3] It did not study lemborexant and cannot show that Dayvigo improves or suppresses testosterone, libido, erections, orgasm, or relationship satisfaction.

How To Think About New Sexual Symptoms

If libido, erections, arousal, orgasm, or genital sensation change after starting Dayvigo, the first step is not automatic discontinuation. The timing matters. Did the symptom begin within days of starting the medicine, after a dose increase, after adding alcohol or another sedating medicine, after a depressive episode, after a new SSRI, or after worsening insomnia?

Sleep duration has been associated with next-day sexual desire and activity in a small prospective study of women, but the study did not test lemborexant. [6] Better sleep may indirectly help some people by reducing exhaustion, while residual sedation, dizziness, or next-day impairment could have the opposite effect. Neither pathway is proof that Dayvigo directly changes sexual function.

What Clinicians Can Document

A practical visit note can stay evidence-based:

• Baseline insomnia pattern and Dayvigo dose
• Timing of sexual symptoms relative to the first dose or dose change
• Other medicines that commonly affect sexual function, including SSRIs, SNRIs, antipsychotics, opioids, finasteride, beta-blockers, and alcohol
• Mood screening, relationship context, and cardiometabolic risk factors
• Whether next-day somnolence or impaired alertness is present

Formal sexual-function questionnaires such as the International Index of Erectile Function or Female Sexual Function Index can help quantify symptoms, but the Dayvigo label does not require routine hormone testing. Testosterone, thyroid, prolactin, or estradiol testing should be driven by symptoms and the patient's broader clinical picture rather than by Dayvigo exposure alone. Readers who want more detail on the drug's sleep mechanism can continue to our lemborexant sleep-architecture review.

Does Dayvigo Affect Sexual Function?

Does Dayvigo cause sexual side effects? Current labeling does not identify sexual dysfunction as a named adverse reaction, and available insomnia trials do not show a clear signal. Does Dayvigo improve sexual function? That is not established. Better sleep may help desire and energy in some people, but Dayvigo is not a libido or erectile-dysfunction treatment.

Talk to the prescriber promptly if sexual symptoms are distressing, if they coincide with depression or suicidal thoughts, if next-day impairment is significant, or if other sedatives or alcohol are involved. The label warns that other central nervous system depressants and alcohol can increase impairment. [1] The AASM insomnia medication guideline predates lemborexant, so it provides general treatment context rather than a Dayvigo-specific recommendation. [4]